Developer docs
API playgroundTry for free, no card

Search company profiles

Noramco

Full company profile

uuid00084oy

Namestring
Noramco
Legal namestring
Noramco, LLC
Websiteurl
noramco.com
Company typeenum
Private
Founded yearint
1979
Descriptiontext

Noramco was a Delaware-incorporated, privately held contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredient (API) and drug substance production for the global pharmaceutical industry. Founded in 1979 in Wilmington, Delaware, the company operated a 150-cubic-meter reactor facility designed for commercial-scale manufacturing of innovative and controlled substances, supported by wholly-owned subsidiaries Purisys (Athens, Georgia, focused on early-phase development and custom synthesis) and Extractas Bioscience (Westbury, Tasmania, focused on alkaloid raw materials extraction). All three sites operated under cGMP API manufacturing standards with regulatory certifications enabling supply into 180+ countries and a track record of passing 100+ global inspections.

The company's core capability was integrated drug-substance manufacturing spanning custom synthesis, process development, scale-up, and GMP-compliant commercial production, with particular depth in DEA-regulated controlled substances and botanical alkaloid extraction — a relatively scarce specialization within the broader CDMO landscape. Noramco served two primary customer segments: global pharmaceutical companies requiring reliable commercial API supply and controlled-substance manufacturing capacity, and emerging biotechnology companies needing early-phase development, clinical-trial material production, and technology transfer support. GTM was enterprise field sales with direct contracts, project-based pricing, and long-term supply agreements, marketed through pharmaceutical industry conferences and direct business-development engagement rather than consumer channels.

Noramco was owned by private investment firm SK Capital Partners as part of the Noramco Group, which had been assembled through SK Capital's 2023 acquisition of Halo Pharma from Cambrex. In January 2026, SK Capital signed a definitive agreement to sell Noramco, Extractas Biosciences, and Purisys to Swiss-listed CDMO Siegfried Holding AG at a valuation multiple below 10x EV/EBITDA, completing the transaction in May 2026; SK Capital concurrently retained Halo Pharmaceuticals as a standalone drug-product CDMO. Following closing, Noramco's Wilmington facility became one of Siegfried's five "run and deliver" sites for established processes, integrated into Siegfried's 13-site global manufacturing network.

Short descriptiontext

Noramco was a US-based, privately held CDMO specializing in active pharmaceutical ingredient (API) and controlled-substance manufacturing for global pharmaceutical and biotech companies, operating facilities in Wilmington (Delaware), Athens (Georgia), and Tasmania (Australia) under cGMP standards before its 2026 acquisition by Siegfried Holding AG.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWilmington, United States
HQ citystring
Wilmington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical API manufacturing, contract development manufacturing, drug substance services, controlled substance API, custom synthesis CDMO
Industry3 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical API Contract Manufacturing (CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services
TypeProfessional Services
Description

Noramco generated revenue through contract manufacturing of active pharmaceutical ingredients and drug substances for pharmaceutical companies. Services included custom synthesis, early-phase development, scale-up, and commercial production under cGMP standards. The business operated on a project-by-project basis with long-term supply agreements.

siegfried.ch
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Noramco is a pharmaceutical contract development and manufacturing organization (CDMO) that produces active pharmaceutical ingredients (APIs) and drug substances for global pharmaceutical and biotechnology companies. The company operates three manufacturing sites in Wilmington (Delaware, USA), Athens (Georgia, USA), and Westbury (Tasmania, Australia), offering custom synthesis, process development, scale-up, and commercial-scale GMP manufacturing with specialization in controlled substances and alkaloid raw material extraction. Services span early-phase development through commercial production under cGMP standards with certifications to supply 180+ countries.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Noramco was a pharmaceutical contract development and manufacturing organization (CDMO) specializing in drug substance (API) manufacturing. The company operated manufacturing facilities primarily in Wilmington, Delaware, producing active pharmaceutical ingredients and controlled substances for the pharmaceutical industry. Noramco was part of the Noramco Group, which also included Extractas Biosciences and Purisys, before the entire group was sold to Siegfried Holding AG in 2026.

Product and service4 records
1Drug Substance (API) Contract Manufacturing
CategoryAPI Contract Manufacturing
Description

Contract development and manufacturing of active pharmaceutical ingredients (APIs) and drug substances, including custom synthesis, process development, scale-up, and GMP manufacturing for global pharmaceutical companies.

2Controlled Substance API Manufacturing
CategoryAPI Contract Manufacturing
Description

Specialized manufacturing services for controlled substances supporting a wide range of therapeutic applications, with strict regulatory compliance and cGMP manufacturing capabilities.

3Early-Phase Development and Custom Synthesis
CategoryPharmaceutical Development Services
Description

Process development, scale-up, and custom synthesis services supporting customers from preclinical through clinical phases, operated from the Purisys (Athens, Georgia) manufacturing site established in 1982.

4Alkaloid Raw Materials Extraction
CategoryRaw Material Supply
Description

Commercial extraction of alkaloid raw materials from botanical sources, operated from the Extractas Bioscience facility in Westbury, Tasmania, Australia, established in 1975.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-27
Description

Siegfried Holding AG, a Swiss-listed Contract Development and Manufacturing Organization (CDMO), acquired Noramco along with Extractas Biosciences and Purisys from SK Capital Partners. The transaction encompassed three manufacturing sites with approximately 400 employees. The acquisition supports Siegfried's EVOLVE+ strategy to expand US-based manufacturing capacity and add controlled substance manufacturing expertise. Deal valued below 10x EV/EBITDA, expected to close later in 2026.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-20
Description

Ensysce Biosciences partnered with Purisys, LLC (a subsidiary of Noramco, LLC) to support manufacturing of PF614. The FDA provided positive feedback on the manufacturing approach, enabling the company to proceed towards commercial production of this pain relief drug candidate.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Swiss-listed CDMO offering both drug substance and drug product services across a 13-site network. Now Noramco's parent, but historically a direct competitor in API manufacturing with overlapping exclusive synthesis and early-phase capabilities.

TypeDirect peer
Description

Privately held API CDMO specializing in complex small molecules, particle engineering, and GMP manufacturing — a direct competitor to Noramco in custom synthesis and commercial-scale API services for pharma customers.

TypeDirect peer
Description

API and intermediates CDMO now part of Thermo Fisher; Noramco was carved out of Cambrex in 2023, making it a direct former-parent and current competitor in small-molecule API manufacturing.

TypeDirect peer
Description

API and fine chemicals CDMO with controlled-substance and complex-molecule capabilities; competes with Noramco in commercial-scale API supply to global pharma.

TypeDirect peer
Description

Integrated CDMO offering API and drug product services including controlled substances; competes with Noramco for outsourced pharma manufacturing programs.

TypeBroad incumbent
Description

Global CDMO leader with extensive small-molecule API capabilities across multiple sites; broader portfolio but competes with Noramco for complex API and controlled-substance work.

TypeDirect peer
Description

US-based CDMO providing API development, manufacturing, and analytical services to pharma and biotech — a comparable scale and geographic competitor to Noramco.

TypeOthers
Description

Broadly integrated CDMO under Thermo Fisher offering API and drug product services globally; overlaps with Noramco in API supply to pharma customers.

TypeEmerging player
Description

Large Asian API CDMO with rapidly scaled commercial API capacity; competes with Noramco on cost for non-controlled small molecules and increasingly for global pharma contracts.

TypeRegional player
Description

India-based manufacturer with significant API and finished-dose capacity; while primarily a generics manufacturer, its API arm competes with Noramco for outsourced commercial-scale API supply.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Noramco

Pharmaceutical API Contract Manufacturing (CDMO)noramco.com

Noramco was a US-based, privately held CDMO specializing in active pharmaceutical ingredient (API) and controlled-substance manufacturing for global pharmaceutical and biotech companies, operating facilities in Wilmington (Delaware), Athens (Georgia), and Tasmania (Australia) under cGMP standards before its 2026 acquisition by Siegfried Holding AG.

What Noramco does

Noramco was a Delaware-incorporated, privately held contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredient (API) and drug substance production for the global pharmaceutical industry. Founded in 1979 in Wilmington, Delaware, the company operated a 150-cubic-meter reactor facility designed for commercial-scale manufacturing of innovative and controlled substances, supported by wholly-owned subsidiaries Purisys (Athens, Georgia, focused on early-phase development and custom synthesis) and Extractas Bioscience (Westbury, Tasmania, focused on alkaloid raw materials extraction). All three sites operated under cGMP API manufacturing standards with regulatory certifications enabling supply into 180+ countries and a track record of passing 100+ global inspections.

The company's core capability was integrated drug-substance manufacturing spanning custom synthesis, process development, scale-up, and GMP-compliant commercial production, with particular depth in DEA-regulated controlled substances and botanical alkaloid extraction — a relatively scarce specialization within the broader CDMO landscape. Noramco served two primary customer segments: global pharmaceutical companies requiring reliable commercial API supply and controlled-substance manufacturing capacity, and emerging biotechnology companies needing early-phase development, clinical-trial material production, and technology transfer support. GTM was enterprise field sales with direct contracts, project-based pricing, and long-term supply agreements, marketed through pharmaceutical industry conferences and direct business-development engagement rather than consumer channels.

Noramco was owned by private investment firm SK Capital Partners as part of the Noramco Group, which had been assembled through SK Capital's 2023 acquisition of Halo Pharma from Cambrex. In January 2026, SK Capital signed a definitive agreement to sell Noramco, Extractas Biosciences, and Purisys to Swiss-listed CDMO Siegfried Holding AG at a valuation multiple below 10x EV/EBITDA, completing the transaction in May 2026; SK Capital concurrently retained Halo Pharmaceuticals as a standalone drug-product CDMO. Following closing, Noramco's Wilmington facility became one of Siegfried's five "run and deliver" sites for established processes, integrated into Siegfried's 13-site global manufacturing network.

Noramco firmographics

Firmographics
Name
Noramco
Legal name
Noramco, LLC
Website
https://noramco.com
Company type
Private
Founded year
1979
Operating status
Acquired
Headcount range
101–250 employees
Short description
Noramco was a US-based, privately held CDMO specializing in active pharmaceutical ingredient (API) and controlled-substance manufacturing for global pharmaceutical and biotech companies, operating facilities in Wilmington (Delaware), Athens (Georgia), and Tasmania (Australia) under cGMP standards before its 2026 acquisition by Siegfried Holding AG.
Ownership category
akta.pro rank

Noramco industry classification

Industry
Product category
Pharmaceutical API Contract Manufacturing (CDMO)
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)

Keywords

  • Pharmaceutical API manufacturing
  • Contract development manufacturing
  • Drug substance services
  • Controlled substance API
  • Custom synthesis CDMO

Where Noramco is headquartered

Location

Headquarters

HQ city
Wilmington
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Noramco business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: Noramco generated revenue through contract manufacturing of active pharmaceutical ingredients and drug substances for pharmaceutical companies. Services included custom synthesis, early-phase development, scale-up, and commercial production under cGMP standards. The business operated on a project-by-project basis with long-term supply agreements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Noramco product offering

Product offering

Core offering

Noramco is a pharmaceutical contract development and manufacturing organization (CDMO) that produces active pharmaceutical ingredients (APIs) and drug substances for global pharmaceutical and biotechnology companies. The company operates three manufacturing sites in Wilmington (Delaware, USA), Athens (Georgia, USA), and Westbury (Tasmania, Australia), offering custom synthesis, process development, scale-up, and commercial-scale GMP manufacturing with specialization in controlled substances and alkaloid raw material extraction. Services span early-phase development through commercial production under cGMP standards with certifications to supply 180+ countries.

Product overview

Noramco was a pharmaceutical contract development and manufacturing organization (CDMO) specializing in drug substance (API) manufacturing. The company operated manufacturing facilities primarily in Wilmington, Delaware, producing active pharmaceutical ingredients and controlled substances for the pharmaceutical industry. Noramco was part of the Noramco Group, which also included Extractas Biosciences and Purisys, before the entire group was sold to Siegfried Holding AG in 2026.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug Substance (API) Contract Manufacturing Contract development and manufacturing of active pharmaceutical ingredients (APIs) and drug substances, including custom synthesis, process development, scale-up, and GMP manufacturing for global pharmaceutical companies.
  • Controlled Substance API Manufacturing Specialized manufacturing services for controlled substances supporting a wide range of therapeutic applications, with strict regulatory compliance and cGMP manufacturing capabilities.
  • Early-Phase Development and Custom Synthesis Process development, scale-up, and custom synthesis services supporting customers from preclinical through clinical phases, operated from the Purisys (Athens, Georgia) manufacturing site established in 1982.
  • Alkaloid Raw Materials Extraction Commercial extraction of alkaloid raw materials from botanical sources, operated from the Extractas Bioscience facility in Westbury, Tasmania, Australia, established in 1975.

Companies that use Noramco

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Noramco technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Noramco partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Siegfried Holding AGcoreStrategic or Co-development Partner · 27 January 2026Siegfried Holding AG, a Swiss-listed Contract Development and Manufacturing Organization (CDMO), acquired Noramco along with Extractas Biosciences and Purisys from SK Capital Partners. The transaction encompassed three manufacturing sites with approximately 400 employees. The acquisition supports Siegfried's EVOLVE+ strategy to expand US-based manufacturing capacity and add controlled substance manufacturing expertise. Deal valued below 10x EV/EBITDA, expected to close later in 2026.
  • Ensysce BiosciencesminorStrategic or Co-development Partner · 20 November 2025Ensysce Biosciences partnered with Purisys, LLC (a subsidiary of Noramco, LLC) to support manufacturing of PF614. The FDA provided positive feedback on the manufacturing approach, enabling the company to proceed towards commercial production of this pain relief drug candidate.

Scale indicators5 records

Recent moves8 records

Expansion highlights3 records

Noramco competitors and assessment

Company assessment

Broad incumbents

  • Siegfried Holding AG: Swiss-listed CDMO offering both drug substance and drug product services across a 13-site network. Now Noramco's parent, but historically a direct competitor in API manufacturing with overlapping exclusive synthesis and early-phase capabilities.
  • Lonza: Global CDMO leader with extensive small-molecule API capabilities across multiple sites; broader portfolio but competes with Noramco for complex API and controlled-substance work.

Direct peers

  • Hovione: Privately held API CDMO specializing in complex small molecules, particle engineering, and GMP manufacturing — a direct competitor to Noramco in custom synthesis and commercial-scale API services for pharma customers.
  • Cambrex: API and intermediates CDMO now part of Thermo Fisher; Noramco was carved out of Cambrex in 2023, making it a direct former-parent and current competitor in small-molecule API manufacturing.
  • Johnson Matthey Health: API and fine chemicals CDMO with controlled-substance and complex-molecule capabilities; competes with Noramco in commercial-scale API supply to global pharma.
  • Piramal Pharma Solutions: Integrated CDMO offering API and drug product services including controlled substances; competes with Noramco for outsourced pharma manufacturing programs.
  • Alcami: US-based CDMO providing API development, manufacturing, and analytical services to pharma and biotech — a comparable scale and geographic competitor to Noramco.

Others

  • Patheon (Thermo Fisher): Broadly integrated CDMO under Thermo Fisher offering API and drug product services globally; overlaps with Noramco in API supply to pharma customers.

Emerging players

  • WuXi STA: Large Asian API CDMO with rapidly scaled commercial API capacity; competes with Noramco on cost for non-controlled small molecules and increasingly for global pharma contracts.

Regional players

  • Aurobindo Pharma: India-based manufacturer with significant API and finished-dose capacity; while primarily a generics manufacturer, its API arm competes with Noramco for outsourced commercial-scale API supply.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Noramco social profiles

Digital presence

Noramco financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Noramco leadership team

Management profile

Number of profiles

Noramco subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Noramco funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Noramco M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Noramco

What does Noramco do?

Noramco is a pharmaceutical contract development and manufacturing organization (CDMO) that produces active pharmaceutical ingredients (APIs) and drug substances for global pharmaceutical and biotechnology companies. The company operates three manufacturing sites in Wilmington (Delaware, USA), Athens (Georgia, USA), and Westbury (Tasmania, Australia), offering custom synthesis, process development, scale-up, and commercial-scale GMP manufacturing with specialization in controlled substances and alkaloid raw material extraction. Services span early-phase development through commercial production under cGMP standards with certifications to supply 180+ countries.

Is Noramco a public or private company?

Noramco is a private company. It is classified as corporate owned and is currently acquired.

When was Noramco founded?

Noramco was founded in 1979. It employs 101 to 250 people.

Where is Noramco based?

Noramco is headquartered in Wilmington, United States, in the North America region.

How does Noramco make money?

One revenue line is on record: contract Manufacturing Services.

Who are Noramco's main competitors?

Broad incumbents on record are Siegfried Holding AG and Lonza. Direct peers are Hovione, Cambrex, Johnson Matthey Health, Piramal Pharma Solutions and Alcami. Patheon (Thermo Fisher) is listed as an others. WuXi STA is listed as an emerging player. Aurobindo Pharma is listed as a regional player.

Does Noramco have an API?

No public API is recorded for Noramco.

What industry is Noramco in?

Noramco's product category is Pharmaceutical API Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooSpeciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturingThe HPAPI outsourcing market is dominated by four CDMOs—Lonza, Siegfried, Aspen, and Veranova—with Siegfried currently leading with 28 HPAPI drugs, followed by Lonza with 23 and both Aspen and Veranova tied at 15. Siegfried expanded its leadership position through the May 2026 acquisition of Noramco, adding 13 controlled drugs and two US manufacturing sites in Wilmington, Delaware and Athens, Georgia, along with Extractas Bioscience's Westbury site in Tasmania, Australia. Industry analysis suggests specialization strategies are proving successful for three of the four leading CDMOs, with Siegfried focusing on controlled drugs for central nervous system indications and Lonza concentrating on immunosuppressant and cytotoxic oncology products.Pharmaceutical TechnologySpeciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturing - Pharmaceutical TechnologyA market analysis identifies four CDMOs—Siegfried, Lonza, Aspen, and Veranova—as the leading players in outsourced HPAPI (high-potency active pharmaceutical ingredient) manufacturing, with Siegfried leading in HPAPI drug count following its acquisition of Noramco finalized in May 2026. Siegfried's acquisition added two US HPAPI sites and Extractas Bioscience's Tasmanian site, expanding its controlled-drug portfolio to 28 drugs versus Lonza's 23. Lonza has responded by announcing plans to expand ADC payload-linker capabilities at its Visp site in Switzerland by June 2026, positioning itself to compete in the biologic and cytotoxic HPAPI segments.SpecchemonlineSK Capital completes two exitsPrivate investment firm SK Capital Partners has completed two previously announced portfolio company sales: Noramco, Extractas Biosciences, and Purisys were sold to Siegfried, while Phoenix Flavors & Fragrances was sold to Turpaz Industries, with terms undisclosed. SK Capital is retaining Halo Pharmaceuticals, which operates sterile-fill-finish facilities in the US and controlled substance production in Canada, with a sterile injectable manufacturing facility expected online in the second half. Turpaz Industries, which already owns a portfolio of flavors and fragrances companies in North America, stated that Phoenix represents a strong strategic fit for its organization.BioSpaceSK Capital Partners Completes Sale of Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AGAffiliates of funds advised by SK Capital Partners have completed the sale of the Noramco Group (comprising Noramco, Extractas Biosciences, and Purisys) to Siegfried Holding AG, a Swiss-listed Contract Development and Manufacturing Organization. Following the transaction, SK Capital retains ownership of Halo Pharmaceuticals as an independent entity, with CEO Lee Karras and CFO Alan Majewski remaining to lead the business. Jefferies acted as lead financial advisor, with RBC Capital Markets and Rothschild & Co also advising, while Kirkland & Ellis served as legal counsel to the company.citybizSK Capital Completes Sale of Noramco, Extractas Biosciences and Purisys to SiegfriedSK Capital Partners has completed the sale of its Noramco Group businesses—Noramco, Extractas Biosciences, and Purisys—to Siegfried Holding AG, marking a strategic exit from the pharmaceutical ingredients and biosciences portfolio within its life sciences investment platform. The transaction terms were not disclosed, and alongside the sale, leadership transitions see Lee Karras and Alan Majewski remaining with SK Capital to guide Halo Pharmaceuticals, the retained contract development and manufacturing organization. The deal underscores ongoing consolidation in the pharmaceutical CDMO sector, where global players are expanding capabilities through acquisitions of specialized manufacturing platforms.PharmiWeb.comPharmiWeb.com – Thank youPharmiWeb.com is closing after 28 years, having operated since 1998. The company thanks members, advertisers, partners, and readers for their contributions. It notes the site was among the first in the dot-com era.SK CapitalSK Capital Partners Completes Sale of Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AGSK Capital Partners affiliates completed the sale of Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG. SK Capital will retain Halo Pharmaceuticals, and CEO Lee Karras will lead it. Halo expects to launch sterile injectable manufacturing at its Whippany facility in the second half of this year.BioSpaceHalo Pharma to become a stand-alone Drug Product Contract Development and Manufacturing Organization (CDMO)SK Capital Partners has signed a definitive agreement to divest Noramco API-related assets to Siegfried, resulting in Halo Pharma becoming a stand-alone drug product contract development and manufacturing organization (CDMO). L. Lee Karras will become CEO of Halo Pharma upon closing, with the company expanding into sterile fill/finish manufacturing services expected to be operational in the second half of 2026. The transaction, subject to customary closing conditions and regulatory approvals, enables Halo to focus on drug product services in North America from its sites in Whippany, New Jersey and Mirabel, Quebec.GlobeNewswireHalo Pharma to become a stand-alone Drug Product Contract Development and Manufacturing Organization (CDMO)SK Capital Partners has signed a definitive agreement to divest the Noramco API-related assets to Siegfried, enabling Halo Pharma to become a stand-alone drug product contract development and manufacturing organization (CDMO). Halo Pharma, previously part of the Noramco Group after being purchased from Cambrex in 2023, will be led by L. Lee Karras as CEO and will focus on expanding its capabilities, including sterile fill/finish manufacturing expected to come online in the second half of 2026. The restructuring allows for greater focus on drug product services in North America with advanced filling capabilities for vials, syringes, and cartridges.FiercePharmaUPDATE: Noramco divestment continues as it re-establishes CDMO Halo PharmaNoramco is re-establishing Halo Pharma as a stand-alone contract development and manufacturing organization (CDMO) by divesting two facilities in Whippany, New Jersey, and Montreal, with sterile CDMO operations expected to launch in the second half of 2026. Swiss CDMO Siegfried simultaneously announced agreements to acquire three active pharmaceutical ingredient (API) facilities from Noramco Group and Extractas Bioscience—sites in Wilmington, Delaware, Athens, Georgia, and Australia—employing approximately 400 people combined, with Siegfried's share price rising 13% on the news. SK Capital, which owns Noramco and Extractas, is divesting these assets, with Siegfried noting the purchase price was "well below recent expectations for US assets."